PT - JOURNAL ARTICLE AU - Gemzell Danielsson, Kristina AU - Rydelius, Johanna TI - Medical termination of pregnancy from day 85 to day 153 of gestation: A randomized comparison between administration of the initial dose of misoprostol at home or in the clinic AID - 10.1101/2024.08.08.24311688 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.08.24311688 4099 - http://medrxiv.org/content/early/2024/08/09/2024.08.08.24311688.short 4100 - http://medrxiv.org/content/early/2024/08/09/2024.08.08.24311688.full AB - Objectives The objective of this study is to compare two groups of women requiring termination of pregnancy from the gestational age of 85 days. All women will receive Mifepristone during their first visit to the out-patient ward. One group of women will receive Misoprostol to administer the first dose (vaginally) at home and 2 hours later they will be admitted to the in-patient ward. They will be informed to present earlier if they start bleeding or experience pain corresponding to more than normal menstrual cramping.The other group will receive the first dose of Misoprostol (vaginally) when admitted in the in-patient ward (usually in the morning) according to current practice.Primary objective To investigate the proportion of women who are successfully treated as day-care patients (day-care being defined as 9 hours from time of admission).Design The study will be a randomized, controlled, multi-centred open label trial with women recruited from four hospitals in Sweden.Competing Interest StatementKGD reports honoraria for ad hoc lectures or participation on advisory boards from Bayer AG, Organon/MSD, Gedeon Richter, Mithra, Natural Cycles, MedinCell, Ferring, Norgene, Exelgyn, Exeltis, Cirqle, RemovAid, and Obseva. HK-K reports honoraria for lectures, participation in courses, or acting as principal investigator in trials from Abbvie, Actavis, Bayer, Gedeon Richter Exeltis, Nordic Pharma, Natural Cycles, Mithra, Teva, Merck, Organon, Ferring, Consilient Health, Evolan, Natural Cycles, Pharmiva, Dynamic Code, Ellen, Estercare, Pharmiva, Gedea, Gesynta, Essity, Preglife, and Takeda. All other authors declare no competing interests.Clinical Protocols https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000964-27 Funding StatementThis study was funded by grants from Regional funds Vastragotaland ALFGBG3050 and ALFGBG-966228), the Hjalmar Svensson Fund (HJSV2021003) Gothenburg Society of Medicine (974195) Region Stockholm (LS 2018-1257 and RS 2019-1054), the Swedish Research Council (2021-01042) and Region Stockholm and Karolinska Institutet ALF (FoUI-954072).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsGAgestational ageGWgestational weekTOPtermination of pregnancyVASvisual analogue scaleCONSORTConsolidated Standards of Reporting TrialsTENStranscutaneous electrical nerve stimulationPCBparacervical blockIUDintra-uterine deviceCRFcase record formAEadverse eventLPLVlast patient last visitDSMBData and Safety Monitoring BoardPULSwedish: personuppgiftslagen; personal records actICH-GCPInternational Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use – Guideline for Good Clinical Practice